SCHEDULE 13G/A: T. Rowe Price Discloses 2.2% Stake in BIO-TECHNE

T. Rowe Price Associates, Inc. has filed an amendment to its Schedule 13G, reporting a 2.2% beneficial ownership stake in BIO-TECHNE CORP common stock as of September 30, 2025.

Summary

• T. Rowe Price Associates, Inc. reported beneficial ownership of 3,350,818 shares of BIO-TECHNE CORP common stock.
• This represents 2.2% of the issuer's common stock.
• The filing is an Amendment No. 3 to a Schedule 13G, indicating a passive investment position.
• T. Rowe Price holds sole voting power over 3,227,315 shares and sole dispositive power over 3,350,144 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of BIO-TECHNE CORP.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of passive institutional ownership, providing neutral information without indicating positive or negative developments for the issuer.

Future Outlook

NA

Industry Context

Schedule 13G filings provide transparency into significant passive institutional ownership, indicating that a major investment firm like T. Rowe Price holds a notable, non-controlling stake in BIO-TECHNE CORP. This type of filing is common for investment advisers managing client assets.

Stakeholder Impact

• Provides transparency to shareholders and the market regarding T. Rowe Price Associates, Inc.'s passive investment in BIO-TECHNE CORP, confirming institutional confidence without implying control or activist intent.

Key Dates

Keywords

BIO-TECHNE CORP, T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Investment Adviser, 09073M104